There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .
Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy.
OBJECTIVE To compare the incidence of repeated red blood cell ( RBC ) transfusion in anemic gynecologic cancer patients receiving platinum-based chemotherapy comparing intravenous and oral iron . MATERIAL S AND METHODS Forty-four anemic gynecologic cancer patients ( hemoglobin level below 10 mg/dl ) who required RBC transfusion were stratified and r and omized according to baseline hemoglobin levels and chemotherapy regimen . Study group received 200 mg of intravenous iron sucrose and control group received oral ferrous sulphate 600 mg/day . RBC transfusion requirement in the consecutive cycle of chemotherapy was the primary outcome . Quality of life was evaluated by vali date d Thai version of the Functional Assessment of Cancer Therapy-Anemia ( FACT-An ) . RESULTS In a total of the 44 patients , there were 22 patients in each group . Five patients ( 22.7 % ) in the study group and 14 patients ( 63.6 % ) in the control group required RBC transfusion in consecutive cycle of chemotherapy ( p=0.01 ) . No significant difference in baseline hemoglobin and hematocrit levels was demonstrated in both groups . Significantly higher mean hemoglobin and hematocrit levels after treatment were reported in the study group ( 10.0+/-0.8 g/dl and 30.5+/-2.4 % ) than the control group ( 9.5+/-0.9 g/dl and 28.4+/-2.7 % ) . No significant change of total FACT-An scores was noted between before and after treatment in both groups . No serious adverse events were reported and there was no significant difference among adverse events between both groups . CONCLUSION Intravenous iron is an alternative treatment for anemic gynecologic cancer patients receiving platinum-based chemotherapy and reduces the incidence of RBC transfusion without serious adverse events
There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .